In LPS-induced rat models, procainamide treatment not only inhibits the overexpression of DNMT1 but also reduces the excessive production of IL-6 in rats with rhabdomyolysis, thereby improving renal function (72). The gene discussed is IL6; the disease is rhabdomyolysis.